Work

A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps3651

Authors: Eelke Gort, Melissa Lynne Johnson, Jimmy J. Hwang, Shubham Pant, Ulrich Dünzinger, Kathrin Riemann, Thomas Kitzing, Pasi A. Janne

Institutions: University Medical Center Utrecht, Sarah Cannon, Levine Cancer Institute, The University of Texas MD Anderson Cancer Center, Boehringer Ingelheim (Germany), Dana-Farber Cancer Institute

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3030382128

Cites:

Cited by: 37

Related to: 10